JAC Advance Access originally published online on December 4, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 4-9
© 2004 The British Society for Antimicrobial Chemotherapy
Leading Article |
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
Clinical Development, Merck & Co., Inc., West Point, PA, USA
Boosted protease inhibitor regimens combine ritonavir with a second, ‘boosted’ protease inhibitor to enhance patient exposure to the latter agent, thereby preventing or overcoming resistance and allowing less frequent dosing, potentially improving adherence. The advantages offered by ritonavir boosting are primarily attributable to the drug’s pharmacokinetic properties. Ritonavir’s inhibition of the cytochrome P-450 CYP3A4 enzyme reduces the metabolism of concomitantly administered protease inhibitors and changes their pharmacokinetic parameters, including area under the curve (AUC), maximum concentration (Cmax), minimum concentration (Cmin) and half-life (t1/2). As a result, the bioavailability of the boosted protease inhibitor is increased and improved penetration into HIV reservoirs may be achieved. Boosted protease inhibitor regimens that utilize a low dose of ritonavir (100–200 mg) appear to offer the best balance of efficacy and tolerability. At this dose, ritonavir boosts the bioavailability of the second protease inhibitor without contributing significantly to the side effect profile of the regimen. In clinical trials, regimens boosted with low dose ritonavir have demonstrated high levels of viral suppression in both antiretroviral naïve patients and patients who previously failed antiretroviral therapy, including protease inhibitor therapy. Side effects observed have generally been similar to those associated with the boosted protease inhibitor. Based upon their enhanced drug exposure and demonstrated efficacy, the boosted ritonavir regimens should be among the first options considered for use in clinical practice.
Keywords: pharmacokinetics, pharmacodynamics, clinical experience, dosing, tolerability
* Corresponding author. Tel: +1-215-328-2280; Fax: +1-215-328-2444; E-mail: robert_zeldin{at}merck.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Vermeir, S. Lachau-Durand, G. Mannens, F. Cuyckens, B. van Hoof, and A. Raoof Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy Subjects Drug Metab. Dispos., April 1, 2009; 37(4): 809 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sankaranarayanan, M. A. Holahan, D. Colussi, M.-C. Crouthamel, V. Devanarayan, J. Ellis, A. Espeseth, A. T. Gates, S. L. Graham, A. R. Gregro, et al. First Demonstration of Cerebrospinal Fluid and Plasma A{beta} Lowering with Oral Administration of a {beta}-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 131 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. van der Lugt, R. S. Autar, S. Ubolyam, E. F. Garcia, J. Sankote, A. Avihingson, T. Chuenyam, D. A. Cooper, J. Lange, P. Phanuphak, et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults J. Antimicrob. Chemother., May 1, 2008; 61(5): 1145 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Healan-Greenberg, J. F. Waring, D. J. Kempf, E. A. G. Blomme, R. G. Tirona, and R. B. Kim A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor Drug Metab. Dispos., March 1, 2008; 36(3): 500 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Y. Poon, S. L. Kosakovsky Pond, D. D. Richman, and S. D. W. Frost Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients J. Virol., December 15, 2007; 81(24): 13598 - 13607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Youle Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients J. Antimicrob. Chemother., December 1, 2007; 60(6): 1195 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Dixit, N. Hariparsad, F. Li, P. Desai, K. E. Thummel, and J. D. Unadkat Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions Drug Metab. Dispos., October 1, 2007; 35(10): 1853 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Boffito, D. Maitland, and A. Pozniak Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies J. Clin. Pharmacol., February 1, 2006; 46(2): 130 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Hammer Clinical practice. Management of newly diagnosed HIV infection. N. Engl. J. Med., October 20, 2005; 353(16): 1702 - 1710. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Sadee and Z. Dai Pharmacogenetics/genomics and personalized medicine Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R207 - R214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Krikorian and D. C. Rudorf Drug-Drug Interactions and HIV Therapy: What Should Pharmacists Know? Journal of Pharmacy Practice, August 1, 2005; 18(4): 278 - 294. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Scott Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 809 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. S. Rhame, S. L. Rawlins, R. A. Petruschke, T. A. Erb, G. A. Winchell, H. M. Wilson, J. M. Edelman, and M. A. Abramson Pharmacokinetics of Indinavir and Ritonavir Administered at 667 and 100 Milligrams, Respectively, Every 12 Hours Compared with Indinavir Administered at 800 Milligrams Every 8 Hours in Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4200 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Armbruster, G. M. Stiegler, B. A. Vcelar, W. Jager, U. Koller, R. Jilch, C. G. Ammann, M. Pruenster, H. Stoiber, and H. W. D. Katinger Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12 J. Antimicrob. Chemother., November 1, 2004; 54(5): 915 - 920. [Abstract] [Full Text] [PDF]
|
|